ScholarIQanswers from OpenAlex

Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis

PaperCitations, authors & open-access status

Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis have?

ScholarIQcitation count

Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis has 54 citations in the OpenAlex counts ScholarIQ stores.

When was Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis published?

ScholarIQyear

Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis has 2007 year in the ScholarIQ index.

What is the open-access status of Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis?

ScholarIQoa status

Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis has green oa status in the ScholarIQ index.

What is the DOI of Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis?

ScholarIQdoi

The DOI for Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis is on the source record.

What is the PMID of Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis?

ScholarIQpmid

The PMID for Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis is on the source record.

What is the OpenAlex record for Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis?

ScholarIQopenalex

The OpenAlex for Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial